APONTIS PHARMA Kicks Off 2024: Revenue Growth, Positive Net Results Confirmed

• APONTIS PHARMA started the financial year 2024 with growth in revenue of Single Pill combinations and a positive net result.
• The revenue of Single Pill combinations increased to EUR 8.8 million in Q1 2024, up from EUR 6.6 million in the same period in 2023.
• The company's EBITDA improved to EUR 1.0 million due to a reduced cost base and higher revenue of Single Pill combinations.
• The net result was profitable again at EUR 0.4 million, compared to a loss of EUR 1.5 million in the same period in 2023.
• APONTIS PHARMA confirmed its increased forecast for the financial year 2024 as a result of the distribution and marketing agreement with Novartis.
• The company expects an increase in sales to EUR 50.7 million and positive EBITDA of EUR 3.3 million for the financial year 2024.

The price of APONTIS PHARMA at the time of the news was 8,3700EUR and did not change compared to the previous day.
14 minutes after the article was published, the price was 8,3600EUR this corresponds to a minus of -0,12 % since publication.

APONTIS PHARMA

-4,03 %

+0,68 %

+7,26 %

+35,47 %

+4,98 %

-54,45 %

-52,06 %

ISIN:DE000A3CMGM5WKN:A3CMGM

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• Max